HMGB1 is involved into the anti-ischemic stroke effect of ginsenoside Rg1 in diabetic rats
10.16438/j.0513-4870.2018-0239
- VernacularTitle:HMGB1参与人参皂苷Rg1改善糖尿病大鼠缺血性脑卒中的作用
- Author:
Shi-feng CHU
1
;
Xin ZHOU
1
;
Zhao ZHANG
1
;
Chen CHEN
1
;
Piao LUO
1
;
Nai-hong CHEN
1
Author Information
1. Institute of Materia Medica, Neuroscience Center, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China
- Publication Type:ORIGINAL ARTICLES
- Keywords:
ginsenoside Rg1;
ischemic stroke;
diabetes mellitus;
high mobility group protein;
neuro-inflammation
- From:
Acta Pharmaceutica Sinica
2018;53(6):958-965
- CountryChina
- Language:Chinese
-
Abstract:
Ginsenoside Rg1 is a common component of a variety of stroke and diabetes medications, but its anti-stroke effect in diabetic patients is unclear. The aim of this research is to test the therapeutic effect of Rg1 on ischemic stroke in diabetic rats, and elucidate the effect of Rg1 on post-stroke neuro-inflammation. Rg1 significantly reduced the infarct area percent, increased the behavioral score, and reduced the brain water content in diabetic rats after stroke in the diabetic rats. Rg1 reduced the post-stroke inflammatory response and decreased the expression of high mobility group box1 (HMGB1) protein significantly. Elevated level of HMGB1 activity by supplementing exogenous HMGB1 protein abolished the anti-stroke effect of Rg1, which suggests that HMGB1 is involved into the anti-stroke effect of Rg1 in the diabetic rats.
